The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-08-20
DOI
https://doi.org/10.1158/1078-0432.ccr-25-0430
Citations
3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
2.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

Federico Cappuzzo, Giuseppe Curigliano, Stefano Tamberi, Roberto Bordonaro et al.
3 citations
Clinical Cancer Research
Cancer Genomics and Diagnostics
2.81
article

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

Federico Cappuzzo, Giuseppe Curigliano, Stefano Tamberi, Roberto Bordonaro, Mauro Biffoni, Fabio Puglisi, Giuseppe Giannini, Elisabetta Fenocchio, Umberto Malapelle, Bruna Cerbelli, Stefania Gori, Agnese Fabbri, Andrea Botticelli, Federica Mazzuca, Simona Pisegna, Paolo A. Ascierto, Alberto Zambelli, Valentina Guarneri, Giulio Metro, Pierfranco Conté, Maurizio Simmaco, Simone Scagnoli, Lorenzo Fornaro, Edoardo Crimini, Paolo Marchetti, Giovanni Blandino, Donatella Marino, Sara Lonardi, Maurizio Ceracchi, Daniele Pozzessere, Massimo Aglietta, Giulia d’Amati, Giuseppe Tonini, Sergio Bracarda, Sofia Verkhovskaia, Andrea DeCensi, Marianna Nuti, Ugo De Giorgi, Giancarlo Pruneri, Lucia Del Mastro, Annamaria Pessino, Chiara Cremolini, Lidia Strigari, Giovanni Butturini, Ettore Capoluongo, Nello Martini
article en
3 citations

Abstract

The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7.

Clinical Cancer ResearchVol. 32(1)
University of Pisa (IT), University of Verona (IT), University of Udine (IT), Istituto Nazionale di Statistica (IT), University of Padua (IT), Università Campus Bio-Medico (IT), University of Milan (IT), University of Perugia (IT), Istituto Superiore di Sanità (IT), Fondazione Roma (IT), Policlinico Umberto I (IT), Ente Ospedaliero Ospedali Galliera (IT), Associazione Italiana Sclerosi Multipla (IT), Azienda Ospedaliera di Perugia (IT), Rete Europea Dell’Innovazione (Italy) (IT), Fondazione Crui (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale Sacro Cuore Don Calabria (IT), Advanced Computer System (Italy) (IT), Ospedale Garibaldi (IT), Ospedale Papa Giovanni XXIII (IT), Istituto Oncologico Veneto (IT), Ospedale Santa Maria (IT), Istituto Dermopatico dell'Immacolata (IT), CTO Andrea Alesini (IT), Federico II University Hospital (IT), Azienda USL di Bologna (IT), National Institute of Health (AM), Ospedale per gli Infermi (IT), Azienda Ospedaliera S.Maria (IT), National Cancer Institute (UA), Azienda Ospedaliera Sant'Andrea (IT), Ospedale di Belcolle (IT), Department of Medical Sciences (BY), A. O. Ordine Mauriziano di Torino (IT), IRCCS San Camillo Hospital (IT), National Cancer Institute (MY), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Campus Bio Medico University Hospital (IT), Tumori Foundation (US), Ospedale Policlinico San Martino (IT), Candiolo Cancer Institute (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto Pasteur (IT), Ospedale di Prato Santo Stefano (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), European Institute of Oncology (IT), University of Milano-Bicocca (IT), University of Naples Federico II (IT), University of Genoa (IT), Sapienza University of Rome (IT)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, Merck KGaA, Novocure, Les Laboratories Pierre Fabre, BeiGene, Incyte, Galecto, Seagen, Eisai, Istituto Superiore di Sanità, Astellas Pharma, Servier, PharmaMar, Ipsen, Italfarmaco, Agenzia Italiana del Farmaco, Ministero della Salute, Daiichi Sankyo Europe
Openalex Percentile: Top 9%
Cancer Genomics and Diagnostics
2.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.